Dihexa for EBV & Glandular Fever Brain Fog: Epstein-Barr Reactivation, the MS Link, Long COVID & the 2026 UK Review

“I had glandular fever months ago — so why can’t I think straight?” Epstein-Barr virus (EBV) is one of the most common viruses on earth: roughly 90–95% of adults carry it for life, usually after a silent childhood infection or a teenage bout of glandular fever (infectious mononucleosis). Most people shrug it off in two to four weeks — but a meaningful minority are left with weeks to months of fatigue and brain fog, and some progress to post-viral fatigue or ME/CFS. In 2022 a landmark Science study of 10 million people showed EBV raises the risk of multiple sclerosis 32-fold, and by late 2025 the first EBV vaccine trials in early MS were underway. That has driven a wave of interest in whether anything can clear the cognitive aftermath. This 2026 UK review walks through EBV reactivation, the neuroinflammatory biology of post-viral fog, the MS and long COVID links, and where Dihexa — a positive modulator of the HGF/c-Met synaptogenesis pathway — actually sits in the evidence hierarchy. The short version: mechanistically interesting, clinically unproven, and carrying a c-Met oncology concern that matters more for an oncogenic virus than almost anywhere else on this site.

EBV & Glandular Fever Brain Fog in 2026: Where the UK Stands

Epstein-Barr virus is so common it is almost a rite of passage. Around 90 to 95% of adults carry it, most having caught it in childhood with no symptoms at all. When primary infection is delayed to adolescence or early adulthood — the classic pattern in the UK — it often presents as glandular fever (infectious mononucleosis): the triad of sore throat, swollen lymph glands and profound fatigue, frequently with fever, an enlarged spleen and abnormal liver function. Incidence peaks between ages 15 and 24, at roughly 5 per 1,000 in the general population.

For most people the acute illness settles within two to four weeks. The problem — and the reason this page exists — is the tail. A substantial minority describe a period of weeks to months in which the sore throat and swollen glands have gone but the fatigue and the fog have not: forgetfulness, slowed processing, difficulty holding a train of thought, word-finding lapses, and the sense that mental tasks that used to be effortless now cost real energy. In a subgroup, that tail does not resolve, and the picture meets the criteria for ME/CFS.

The numbers behind that subgroup are sobering. Around 60% of people with ME/CFS report an infectious onset, and EBV mononucleosis is the single most frequently named trigger. A 2024 one-year follow-up of young people with ME/CFS following EBV mononucleosis documented just how persistent the post-viral course can be, and the IMMUC study (2024) set out to identify which young people are most at risk of postviral symptoms after EBV mono in the first place.

Against that backdrop, the same self-experimentation culture that has formed around brain fog in long COVID, Lyme disease, fibromyalgia and menopause has surfaced Dihexa as a candidate for post-EBV cognitive symptoms. The question this article takes seriously is whether the science supports that step — or whether, for most people, the unglamorous answer is the right one: rest, pace, sleep, treat the treatable, and let the immune system finish the job.

The 2026 Biology of EBV & Post-Viral Brain Fog

Brain fog after EBV is not a single thing. Several mechanisms operate in parallel, and their relative weight differs between a recent glandular-fever convalescence, a chronic reactivation picture, and a fully developed post-viral syndrome.

Persistent Neuroinflammation and Cytokines

The dominant theme in 2026 is immune. EBV produces viral proteins that keep the immune system engaged long after the acute illness, driving elevated inflammatory cytokines that are themselves cognitively impairing. A 2025 Frontiers in Immunology review argues the cognitive impact of EBV has been systematically underestimated, and a 2024 review in PMC frames an abnormal long-term immune response to EBV as central to its effect on cognition. The working model is that low-grade neuroinflammation and microglial activation degrade the efficiency of memory and executive circuits without producing the gross structural damage seen in acute encephalitis.

The Hippocampus and Memory

The hippocampus is central to memory and learning and is unusually sensitive to inflammatory signalling. Across viral CNS conditions, persistent neuroinflammation and microglial proliferation in and around the hippocampus track with the cognitive sequelae patients report. The relevant detail for the Dihexa question is that the hippocampus is also one of the regions where the HGF/c-Met synaptogenesis system and BDNF-driven plasticity remain active in adulthood — so the anatomy of the deficit overlaps with the anatomy of the proposed mechanism.

Autophagy Interference and Mitochondrial Dysfunction

EBV interferes with autophagy — the cellular housekeeping process that clears damaged components. Reduced autophagy contributes to mitochondrial dysfunction, a core feature of ME/CFS and a plausible contributor to the energy-limited, post-exertional quality of post-viral fog. This is a mechanism Dihexa does not address: a synaptogenic peptide does nothing for cellular energy metabolism or the underlying viral immune dynamics.

EBV Reactivation vs Original Infection

EBV is never fully cleared; it persists latently in B cells for life and can reactivate under stress, other infections or immune perturbation. A portion of “EBV brain fog” reflects reactivation rather than the original glandular fever. Reactivation is one of the most discussed mechanisms in long COVID (see below) and is relevant to chronic active EBV, a rare and serious condition distinct from everyday post-viral fatigue.

Sleep, Deconditioning and Mood

A prolonged illness disrupts sleep, reduces physical activity and frequently lowers mood — each of which independently impairs cognition. Disentangling “EBV fog” from the deconditioning and sleep disruption of being unwell for months is genuinely difficult, and it matters: the treatable contributors here are addressable without any experimental compound.

The EBV–MS Link: Why This Virus Is Suddenly Everywhere

For decades EBV was suspected of involvement in multiple sclerosis, but the evidence was circumstantial. That changed in January 2022. A team led by Alberto Ascherio at the Harvard T.H. Chan School of Public Health published a longitudinal analysis in Science of more than 10 million US military personnel followed over two decades. The risk of developing MS rose 32-fold after EBV infection — and was essentially unchanged after infection with other viruses, including the structurally similar cytomegalovirus. Ascherio described it as the first study providing compelling evidence of causality.

Weeks later, a 2022 Nature study by Lanz and colleagues supplied a mechanism. Clonally expanded B cells in MS patients produced antibodies against the EBV protein EBNA1 that cross-react with GlialCAM, a glial cell adhesion protein in the central nervous system — a textbook case of molecular mimicry, where an immune response aimed at a virus mistakenly attacks the brain. Elevated EBNA1/GlialCAM reactivity appeared in roughly 20–25% of MS cohorts. A 2023 Lancet Neurology review laid out the prevention-and-therapy implications.

The crucial nuance, often lost in headlines, is that EBV is now considered necessary but not sufficient for MS. Almost everyone with MS has had EBV — but the overwhelming majority of the ~95% of adults who carry EBV never develop MS. Glandular fever is not a sentence of future MS, and post-EBV brain fog is not early MS. What the link does is reframe EBV from a trivial childhood virus into a serious long-term player in neurological disease — which is exactly why it is now a vaccine target, and why interest in “clearing” EBV has surged. For the cognition-after-glandular-fever question, the MS story is context, not a treatment rationale.

EBV Vaccines and the 2025–2026 News

The EBV–MS evidence has accelerated vaccine development. As of 2026 there is still no licensed EBV vaccine, but several candidates are in clinical trials, and the news flow is the main reason EBV is in the headlines.

• Moderna mRNA EBV vaccine. Moderna has advanced mRNA candidates including a prophylactic vaccine aimed at preventing glandular fever. In late 2025, an mRNA EBV candidate entered a Phase 2 trial in people with early relapsing MS (NCT06735248), aiming to enrol around 180 EBV-seropositive adults diagnosed within the previous two years, with the study running until 2029. The UK MS Society has covered the trial for a UK audience.
• NIH gp350-ferritin nanoparticle vaccine. The US National Institutes of Health has tested a gp350-ferritin nanoparticle vaccine in early-phase trials in healthy adults, targeting the glycoprotein EBV uses to enter B cells.
• Therapeutic vs prophylactic. A vital distinction: a prophylactic vaccine aims to prevent EBV infection (and downstream glandular fever or MS) in people not yet infected; a therapeutic approach aims to alter disease in people already infected. Neither is a treatment for existing brain fog.

The honest framing for anyone reading this with post-EBV fog: these programmes are genuinely exciting and years away from routine use. None of them is a route to clearing brain fog you already have, and none of them has any relationship to Dihexa. They matter here only as the reason EBV is suddenly a hot topic — and a reminder that the serious science is happening in regulated trials, not in the peptide market.

The Long COVID and ME/CFS Overlap

Post-EBV fog does not sit in isolation. It overlaps heavily with the broader family of post-viral syndromes, and EBV keeps reappearing inside them.

In long COVID, EBV reactivation is one of the most consistently reported associations. Studies have found EBV reactivation markers in a large fraction of long COVID patients — one widely cited analysis reported reactivation in around 67% of long COVID cases versus ~10% of controls — and a 2022 Cell study by Su and colleagues identified circulating EBV at the time of acute infection as one of several early predictors of post-acute COVID-19. The current model treats persistent SARS-CoV-2, EBV and other herpesvirus reactivation (such as HHV-6), autoimmunity and microclotting as overlapping, not competing, mechanisms.

In ME/CFS, the EBV connection is older and arguably stronger: mononucleosis is the most commonly reported infectious trigger, and reactivation of latent herpesviruses including EBV is a recurring theme in the pathophysiology. The shared thread — immune dysregulation, post-exertional symptom worsening, mitochondrial involvement and brain fog — is why these conditions are increasingly studied together.

For the Dihexa question, the overlap cuts two ways. It widens the population searching for cognitive help (and therefore the audience tempted by unlicensed peptides), and it underscores how poorly understood the underlying biology still is. A synaptogenic peptide does not touch viral reactivation, immune dysregulation or mitochondrial energy failure — the mechanisms that actually drive these syndromes.

Where Dihexa Enters: The HGF/c-Met & BDNF Synapse Story

To understand why anyone considers Dihexa here at all, you have to follow the mechanism to the one place it overlaps with post-viral fog: the synapse.

Inflammatory and energy-limited states reduce the brain’s capacity to build and maintain dendritic spines — the tiny protrusions where excitatory synapses form. BDNF (brain-derived neurotrophic factor), the master regulator of activity-dependent plasticity, supports spine maturation through its TrkB receptor, and BDNF signalling is suppressed by chronic inflammation and stress. Independently, hepatocyte growth factor (HGF) acting on its receptor c-Met drives synaptogenesis through the PI-3K/AKT and MAPK pathways — a parallel route to the same cellular output. Peak MET expression in cortex coincides with periods of rapid synaptogenesis, and the system stays active in the adult hippocampus and prefrontal cortex.

Dihexa — a small peptide analogue derived from angiotensin IV — is a positive modulator of the HGF/c-Met pathway. Full molecular detail lives on the mechanism of action page. The relevance to post-EBV brain fog rests on three points of overlap:

• Synaptogenesis as the inverse of inflammatory synapse loss. Chronic neuroinflammation reduces hippocampal spine density; Dihexa promotes dendritic spine formation in cell culture within hours. The end-points are symmetrical. The unresolved question is whether spine induction in a dish translates into measurable cognitive benefit in a chronically inflamed, virally perturbed human brain.
• A route to synaptic support that bypasses BDNF suppression. If inflammation is suppressing BDNF, a pathway that supports synaptic plasticity through a different receptor system is conceptually interesting. The operative word is conceptually; the clinical data to back that reasoning do not exist for any post-viral condition.
• Regional fit. The hippocampus and prefrontal cortex — the regions most implicated in post-viral cognitive symptoms — are among those with the highest density of c-Met receptors in the adult brain, so a c-Met signal lands in roughly the right anatomical place.

This is the mechanistic case for considering Dihexa. The rest of this article is about why the shape of a mechanism is not the same as evidence for an intervention — and why the c-Met biology raises an EBV-specific safety question sharper than almost anywhere else.

Recover First: The Only Evidence-Based Starting Point

Any honest review of post-EBV brain fog has to begin with what actually works for most people: structured recovery. The reassuring fact is that the majority of post-glandular-fever fatigue and fog resolves with time. The job is to support that resolution and avoid the traps that prolong it.

• Graded rest and pacing, not pushing through. Post-viral fatigue often worsens with over-exertion. If there is any hint of post-exertional symptom worsening, pacing — staying within an energy envelope and increasing activity gradually — is the cornerstone, in line with NICE NG206 guidance for ME/CFS. Repeated boom-and-bust cycles are the single most common self-inflicted setback.
• Protect sleep. Consistent sleep timing, limiting evening alcohol and screens, and treating any sleep disruption directly. Sleep is where memory consolidation happens — see sleep & memory consolidation.
• Rule out the treatable imitators. A GP can check a full blood count, ferritin, B12, folate, vitamin D, thyroid function (post-viral thyroiditis can follow infections) and liver function (often abnormal in glandular fever). Iron deficiency and thyroid disease are common, cheap to treat, and easily mistaken for post-viral fog.
• Avoid splenic injury in the acute phase. Glandular fever enlarges the spleen; contact sport and heavy lifting should be avoided for several weeks because of the risk of splenic rupture. This is the one piece of glandular-fever advice that is genuinely urgent.
• Treat mood and anxiety. Low mood and health anxiety are common after a long illness and amplify perceived cognitive symptoms. See anxiety & chronic stress and depression & mood for the synaptic context.
• Gentle, paced re-conditioning. Once post-exertional worsening is excluded, gradual aerobic activity raises BDNF independently of any drug and has the best evidence base of any non-pharmacological intervention for midlife cognition.

For the majority of people with post-EBV cognitive symptoms, this package — rest, pace, sleep, correct deficiencies, treat mood, re-condition gradually — resolves enough of the burden that experimental interventions become unnecessary. Dihexa is not a substitute for recovery. It is, at best, an experimental consideration after the modifiable factors are addressed and symptoms genuinely persist — and even then, only after a frank conversation with a clinician.

The Fosgonimeton Parallel and the Limits of Mechanism

Because no controlled human trial of Dihexa in post-viral disease exists, the most informative clinical-stage comparator is fosgonimeton (ATH-1017), a small-molecule positive modulator of the HGF/MET system developed by Athira Pharma. Fosgonimeton is not Dihexa, but it shares the core mechanism of amplifying HGF/c-Met signalling, and unlike Dihexa it has been tested in humans. The full story is on the dedicated fosgonimeton page.

What fosgonimeton brings to the post-viral question is a sobering lesson in the gap between mechanism and outcome. The active metabolite enhances the HGF/MET system, shows procognitive effects in animal models of neuroinflammation-driven cognitive impairment — precisely the kind of biology relevant to EBV — and was well-tolerated in early human studies. Yet the Phase 3 LIFT-AD trial in Alzheimer’s disease, reporting in 2024, did not meet its primary cognitive endpoint, and the programme was subsequently refocused.

The lesson is direct. A well-validated, well-tolerated, mechanistically coherent approach to the HGF/MET system — including in neuroinflammatory models — failed to produce a measurable clinical win in a cognitively impaired population. Dihexa, whose human data are sparser than fosgonimeton’s and whose chronic-use safety follow-up is effectively absent, inherits that cautionary story. Mechanism-first reasoning is seductive; cognitive endpoints are humbling.

EBV-Specific Risks: c-Met, an Oncogenic Virus and Reactivation

The general Dihexa safety discussion is on the side effects and risks page. Several risks become more pointed in the context of Epstein-Barr virus specifically.

c-Met Activation in a Carrier of an Oncogenic Virus

This is the central EBV-specific concern. HGF/c-Met signalling is pro-proliferative and oncogenically relevant across many tumour types. EBV is itself a recognised oncogenic virus: it is causally associated with Burkitt lymphoma, Hodgkin lymphoma, nasopharyngeal carcinoma, a subset of gastric cancers, and post-transplant lymphoproliferative disease. Pharmacologically amplifying a pro-growth signalling pathway in someone who carries an oncogenic virus — particularly during active infection or reactivation, when EBV-infected B cells are proliferating — is a specific and avoidable theoretical risk. No study has examined Dihexa in any EBV-positive population, and the convergence of “pro-proliferative drug” with “cancer-associated virus” is exactly the kind of combination that warrants caution rather than experimentation.

Immunosuppression and Post-Transplant Status

EBV-driven lymphoproliferative disease is a well-recognised hazard in immunosuppressed and post-transplant patients. Anyone in that category should treat the c-Met concern as a hard stop, not a relative caution. Self-experimentation with a pro-proliferative compound in the setting of impaired EBV immune control is not a reasonable risk.

Active Glandular Fever and Splenomegaly

During acute glandular fever the spleen is enlarged, liver function is frequently deranged, and the immune system is fully occupied. This is not a window for introducing an unlicensed peptide with an uncharacterised interaction profile. The acute-phase priorities are rest and splenic protection, not cognitive enhancement.

Masking Treatable Contributors

The most consequential everyday risk is shared with long COVID and menopause: an unlicensed compound that produces a non-specific lift in perceived clarity can delay an assessment that would otherwise pick up iron deficiency, B12 deficiency, vitamin D deficiency, post-viral thyroiditis, depression, sleep disruption or — rarely — the red-flag signs of chronic active EBV or an EBV-associated malignancy. These are genuine, correctable drivers of post-viral cognitive symptoms. Treating them is cheap, safe and available on the NHS. Missing them costs months.

Mood, Sleep and Symptom Variability

Community reports of Dihexa frequently mention vivid dreams, disturbed sleep and, in a minority, mood changes. In a population whose sleep is already disrupted and whose mood is often low after a long illness, the margin for destabilisation is smaller than in healthy younger users. Any worsening of sleep, mood or fatigue in the first week of a trial should be treated as a stop signal.

Strong Placebo Effect and Natural Recovery

This is the methodological trap that makes post-viral self-trials almost uninterpretable. Post-EBV fatigue and fog naturally improve over weeks to months. Anyone who starts an intervention during a symptom trough will, on average, feel better afterwards simply through the natural course of recovery and regression to the mean. An uncontrolled self-trial layered on top of spontaneous recovery is structurally biased towards reading improvement as a treatment effect.

Who Should Not Consider Dihexa for EBV / Glandular Fever Brain Fog

• Anyone with a personal or family history of lymphoma (Burkitt, Hodgkin or non-Hodgkin), nasopharyngeal carcinoma, gastric cancer, or other EBV-associated or hormone-sensitive cancers.
• Anyone who is immunosuppressed, on immunosuppressive medication, or post-organ-transplant — given the recognised risk of EBV-driven lymphoproliferative disease.
• Anyone with active glandular fever, an enlarged spleen, deranged liver function, or any ongoing acute infection.
• Anyone with suspected chronic active EBV or unexplained persistent fevers, weight loss, night sweats or enlarged lymph nodes — these require urgent medical assessment, not peptides.
• Anyone pregnant, breastfeeding, or planning conception.
• Anyone with a diagnosed bipolar or psychotic-spectrum condition, given community reports of peptide-related mood destabilisation.
• Anyone whose post-viral symptoms have not been formally assessed, ideally with a full blood count, ferritin, B12, folate, vitamin D, thyroid and liver function.
• Anyone on multiple licensed medications without clinician oversight of an unlicensed addition.

What the Evidence Actually Supports for EBV Brain Fog in 2026

For balance — and because this is where almost everyone should start — here is what the 2026 evidence base genuinely supports.

• Time and graded recovery. Most post-EBV fatigue and fog resolves. Support that with rest, pacing and a gradual return to activity rather than pushing through.
• Pace if there is post-exertional worsening. Stay within an energy envelope and follow NICE NG206 principles if the picture is shifting towards ME/CFS.
• Rule out imitators. Full blood count, ferritin, B12, folate, vitamin D, thyroid function, liver function. Correct deficiencies before considering any experimental intervention.
• Protect and optimise sleep. Consistent timing, limited evening alcohol, treatment of any specific sleep disorder.
• Treat mood and anxiety. Both respond to evidence-based treatment and strongly improve perceived cognition. See Dihexa for depression & mood for the synaptogenic-hypothesis context.
• Aerobic and resistance exercise, paced. Once post-exertional worsening is excluded, both raise BDNF and have the best effect sizes of any non-pharmacological cognition intervention.
• Cognitive scaffolds. Lists, calendars, voice notes and avoiding self-criticism for cognitive lapses help in post-viral fog as well as anywhere else.
• Vetted UK resources. The NHS glandular fever pages, ME Association and the MS Society (for the EBV–MS context) are reliable UK-specific resources.

If Someone Were Considering It: Practical Realities

This section is descriptive, not prescriptive. There is no validated protocol for Dihexa in EBV or post-viral disease because there is no trial. What follows is context for the realities self-experimenters describe, with caveats that should temper any inference.

• No post-viral-specific dose. Community dosing ranges (covered in the Dihexa dosage guide) were derived from cognitive-enhancement use in predominantly healthy cohorts. Pharmacokinetics in post-viral, fatigued or inflamed populations are not characterised.
• Active infection is an absolute no. Acute glandular fever, ongoing fever, or any reactivation symptoms are not a setting for an unlicensed pro-proliferative compound.
• Short trials, clear off-periods. If used at all, short cycles with defined on/off periods are preferred to continuous use — both to limit sustained c-Met activation in an EBV carrier and to allow evaluation against the backdrop of natural recovery. See the Dihexa Review 2026 for community-reported cycling.
• Stacking is not the answer. Adding Dihexa to an already complex post-viral regime (supplements, sleep aids, mood medication) creates an interaction landscape no one can interpret. The stacking guide cautions explicitly against complex combinations without oversight.
• Track and rule out spontaneous recovery. Post-viral symptoms improve over time and fluctuate week to week. Any intervention started during a trough will look effective in the subsequent rise. Brief structured diaries of sleep, mood, fatigue and cognitive self-ratings are the minimum rigour — and even then, an uncontrolled trial cannot separate drug from natural course.
• Stop at the first adverse signal. New or enlarging lymph nodes, persistent fever, night sweats, unexplained weight loss, worsening fatigue, or mood destabilisation are reasons to stop immediately and seek clinical review.

None of this is endorsement. The strongest practical advice for EBV brain fog in 2026 is the advice that applies before any peptide conversation: rest, pace, sleep, fix the easy deficiencies, treat mood, re-condition gradually, and give recovery time. That is the evidence-based pathway.

The Bottom Line in 2026

EBV and glandular fever brain fog is real, biological, and rooted in a combination of persistent low-grade neuroinflammation, microglial activation, autophagy interference and mitochondrial dysfunction, EBV reactivation, and the sleep, deconditioning and mood effects of a long illness. The dominant intervention — with by far the largest evidence base — is structured recovery: rest, pacing, sleep, deficiency correction, mood treatment and graded re-conditioning, with most people improving over weeks to months.

Dihexa, with its direct activation of the HGF/c-Met spine-formation pathway, is one of the few small molecules whose mechanism plausibly addresses part of the synaptic deficit that inflammation produces. The catch is the same as in every other indication on this site: there is no published, registered clinical trial of Dihexa in any EBV, glandular fever or post-viral population. The closest clinical-stage relative, fosgonimeton, confirmed feasibility of HGF/MET modulation in humans but missed its Phase 3 cognitive endpoint. And the EBV-specific twist — amplifying a pro-proliferative pathway in a carrier of an oncogenic virus — gives this population an extra, pointed reason to pause.

For the majority of people with post-EBV cognitive symptoms, the honest reading of the 2026 evidence is this. Recovery first, deficiency correction second, mood and sleep third, and research chemicals essentially last — if at all. The MS link and the vaccine programmes are genuinely important science, but they are about prevention and disease modification in regulated trials, not about clearing the fog you have today. Dihexa is biologically interesting and clinically unproven. The first call should be a GP appointment, not a peptide vendor.

Frequently Asked Questions

Related Reading on Dihexa.co.uk

• Dihexa for Long COVID Brain Fog (2026) — the closest post-viral phenotype; EBV reactivation is one of the most consistently reported contributors to long COVID.
• Dihexa for ME/CFS (2026) — EBV mononucleosis is the most commonly reported infectious trigger for ME/CFS; the pacing-first, NICE NG206 framework.
• Dihexa for Multiple Sclerosis (2026) — the disease at the centre of the EBV story; the 32-fold link, EBNA1/GlialCAM mimicry and the vaccine programmes.
• Dihexa for Lyme Disease Brain Fog & PTLDS (2026) — the tick-borne post-infection cognitive parallel and its overlapping immune mechanism.
• Dihexa for TBI & Concussion (2026) — another acquired-injury cognitive model where HGF/c-Met biology is discussed.
• Dihexa for Hashimoto’s & Hypothyroid Brain Fog (2026) — post-viral thyroiditis is a treatable imitator that should be screened after glandular fever.
• Dihexa for B12 Deficiency Brain Fog (2026) — a cheap, common, correctable driver of post-viral fog.
• Dihexa for Iron Deficiency & Anaemia Brain Fog (2026) — another key treatable imitator to exclude.
• Dihexa for Vitamin D Deficiency Brain Fog (2026) — commonly low after a prolonged illness and associated with cognitive symptoms.
• Dihexa, Sleep & Memory Consolidation — why protecting sleep is central to post-viral recovery.
• Dihexa for Anxiety & Chronic Stress (2026) — health anxiety after a long illness amplifies perceived cognitive symptoms.
• Dihexa for Depression & Mood — the BDNF-synaptogenesis model and its overlap with post-viral low mood.
• Dihexa vs BDNF: What “10 Million Times More Potent” Actually Means — in-depth look at the BDNF mechanism claim.
• Dihexa Review 2026 — effects timeline, oral vs sublingual, cycling.
• Dihexa Stacking Guide — why most stacks need clinician oversight.
• Mechanism of Action — HGF/c-Met, PI-3K/AKT, dendritic spines.
• Side Effects & Risks — the general safety picture.
• UK Legal Status — where Dihexa sits in UK law and MHRA advertising rules.
• Fosgonimeton & Athira — the cautionary Phase 3 story.

External Authoritative Sources Cited

• Bjornevik K, Cortese M, Ascherio A et al. (Science, 2022). Longitudinal analysis reveals high prevalence of EBV associated with multiple sclerosis.
• Lanz TV et al. (Nature, 2022). Clonally expanded B cells in MS bind EBV EBNA1 and GlialCAM.
• Bjornevik K et al. (Lancet Neurology, 2023). EBV as a cause of MS: opportunities for prevention and therapy.
• Multiple Sclerosis News Today (Nov 2025). Phase 2 trial tests experimental EBV vaccine in early MS.
• MS Society UK. New trial testing vaccine against common virus to treat relapsing MS.
• Su Y et al. (Cell, 2022). Multiple early factors anticipate post-acute COVID-19 sequelae.
• IMMUC Study (medRxiv, 2024). Predictors of postviral symptoms following EBV-associated infectious mononucleosis in young people.
• PMC (2024). One-year follow-up of young people with ME/CFS following infectious mononucleosis by EBV.
• PMC (2024). New insights on the link between EBV infection and cognitive decline in neurodegenerative diseases (Review).
• Frontiers in Immunology (2025). Underestimated virus impaired cognition - more evidence and more work to do.
• Frontiers (2021). HGF and MET: From Brain Development to Neurological Disorders.
• Benoist CC et al. (JPET, 2014). Pharmacological discrimination of Dihexa procognitive effects via HGF/Met.
• NHS — Glandular fever (infectious mononucleosis).
• NICE NG206. Myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome: diagnosis and management.
• ME Association.
• MS Society UK.